Cytokinetics, IncorporatedCYTKNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank57
3Y CAGR-27.1%
5Y CAGR+9.3%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-27.1%/yr
Annual compound
5Y CAGR
+9.3%/yr
Recent deceleration
Percentile
P57
Within normal range
vs 5Y Ago
1.6x
Solid growth
Streak
1 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 19.59% |
| 2024 | 2.81% |
| 2023 | 37.09% |
| 2022 | 50.57% |
| 2021 | 64.97% |
| 2020 | 12.57% |
| 2019 | -3.38% |
| 2018 | -1.29% |
| 2017 | 50.75% |
| 2016 | 29.09% |